

Result Update February 16, 2015

Sharon Bio-Medicine Ltd.

Termination of coverage

Daljeet S. Kohli Head of Research

Tel: +91 22 66188826 daljeet.kohli@indianivesh.in

Tushar Manudhane Research Analyst

Tel: +91 22 66188835 tushar.manudhane@indianivesh.in Sharon Bio-medicine (SBML IN) grossly underperformed in terms of sales, EBITDA as well as adjusted PAT. This is mainly due to y-y contraction in sales coupled with sharp increase in material cost. As a result, SBML reported loss of Rs758mn at EBITDA level compared to operating profit of Rs372mn for Q2FY14. Weak operating performance along with higher interest cost resulted in loss of Rs921mn against profit of Rs171mn at net income level. As of now, there is no visibility on USFDA inspection at its manufacturing facility, which was one of the key trigger for business growth. Though the key trigger was taking time to pan out, operating profit of base business was sufficient to compensate interest outgo. However, Q3FY15 result indicates pain in base business as well. Hence, we terminate our coverage on the lack of any major driver for growth in business of SBML and low visibility on sustainability of operating profit of base business going forward.

SBML IN (Rs Mn)	Q2FY15	Q2FY14A	Q1FY15A	Y-o-Y Ch.(%)	Q-o-Q Ch. (%)	INSPL est.	Variance
Sales	2,385	3,359	13,248	(29.0)	(82.0)	3,503	(31.9)
EBITDA	(758)	372	1,575	(303.7)	(148.1)	333	(327.6)
Adj Net Profit	(921)	171	703	(638.8)	(231.0)	140	(757.6)
Reported Net Profit	(1,076)	160	758	(773.0)	(241.9)	140	(868.5)

Source: IndiaNivesh Research

Quarterly results summary

Particulars (Rs Mn)	Q2FY15	Q2FY14	Y-o-Y	1QFY15	Q-o-Q	1HFY15	1HFY14	Y-o-Y
Net Sales	2,385	3,359	(29.0)	3,249	(26.6)	5,634	6,513	(13.5)
Other Income			-		-	-	4	-
Total Income	2,385	3,359	(29.0)	3,249	(26.6)	5,634	6,517	(13.6)
Consumption of raw material	3,100	2,878	7.7	2,678	15.8	5,778	5,584	3.5
Employee Cost	28	53	(47.1)	66	(57.9)	94	105	(10.3)
Other Expenditure	15	59	(74.9)	119	(87.7)	134	115	16.4
Total Expenditure	3,143	2,989	5.1	2,863	9.8	6,006	5,804	3.5
EBITDA	(758)	370	(304.7)	386	(296.3)	(372)	714	(152.1)
Depreciation & Amortization	30	41	(27.5)	30	(0.7)	60	82	(26.3)
EBIT	(788)	329	(339.6)	356	(321.5)	(432)	632	(168.4)
Other Income	2	-	NA	11	(84.7)	12	-	NA
Interest	166	137	21.6	140	19.0	306	250	22.5
Pre-tax Profit	(952)	192	(595.7)	227	(520.0)	(725)	383	(289.7)
Тах	(31)	34	(191.8)	31	(200.0)	-	68	(100.0)
Profit before minority interest	(921)	158	(682.5)	196	(571.1)	(725)	315	(330.6)
Minority Interest	-	-	-	-	-	-	-	-
Adj net profit	(921)	158	(682.5)	196	(571.1)	(725)	315	(330.6)
Foreign Exchange Gain/(loss), others	155	-	NA	(14)	(1,216.5)	(169)	-	NA
Net Profit (Reported)	(766)	158	(584.4)	182	(521.7)	(895)	315	(384.4)
EPS	(8.7)	1.5	(682.5)	1.9	(571.1)	(6.9)	3.0	(330.6)

<u>Key ratios</u>								
Particulars (%)	Q2FY15	Q2FY14	Bps	1QFY15	Bps	1HFY15	1HFY14	Bps
Gross Margins	(30.0)	14.3	(4,431)	17.6	(4,757)	(2.6)	14.3	(1,683)
EBITDA margin	(31.8)	11.0	(4,279)	11.9	(4,365)	(6.6)	11.0	(1,756)
Net Margin	(38.6)	4.7	(4,333)	6.0	(4,464)	(12.9)	4.8	(1,771)
Material cost/Net Sales	130.0	85.7	4,431	82.4	4,757	102.6	85.7	1,683
Employee Cost/ Net Sales	1.2	1.6	(40)	2.0	(87)	1.7	1.6	6
Other Expenditure/ Net Sales	0.6	1.7	(113)	3.7	(305)	2.4	1.8	61
Tax Rate	3.9	17.7	(1,378)	14.7	(1,075)	-	17.8	(1,775)

Source: Company Filings; IndiaNivesh Research

IndiaNivesh Research

IndiaNivesh Securities Private Limited

601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800

IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV.

Disclaimer: This document has been prepared by IndiaNivesh Securities Private Limited ("INSPL"), for use by the recipient as information only and is not for circulation or public distribution. INSPL includes subsidiaries, group and associate companies, promoters, employees and affiliates. INSPL researches, aggregates and faithfully reproduces information available in public domain and other sources, considered in this document does not represent the views of INSPL and/or its officers, employees and the recipient must exercise independent judgement with regard to such content. This document has been published in accordance with the provisions of Regulation 18 of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is not to be altered, transmitted, reproduced, copied, redistributed, uploaded or published or made available to others, in any form, in whole or in part, for any purpose without prior written permission from INSPL. This document is solely for information purpose and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. Recipients of this document should be aware that past performance is not necessarily a guide for future performance and price and value of investments cang ou por down. The suitability or otherwise of any investments will depend upon the recipients particular circumstances. INSPL does not take responsibility thereof. The research analysts of INSPL have adhered to the code of conduct under Regulation 24 (2) of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is assuch, may not match with a report on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Nothing in this document constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or for any omasis on or for any liability arising from the use of this document. Opinions expressed are our current

This report is based / focused on fundamentals of the Company and forward-looking statements as such, may not match with a report on a company's technical analysis report

Each of the analysts named below hereby certifies that, with respect to each subject company and its securities for which the analyst is responsible in this report, (1) all of the views expressed in this report accurately reflect his or her personal views about the subject companies and securities, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report: Daljeet S Kohli, Amar Maurya, Abhishek Jain, Yogesh Hotwani, Prerna Jhunjhunwala, Kaushal Patel, Rahul Koli, Tushar Manudhane & Dharmesh Kant.

Following table contains the disclosure of interest in order to adhere to utmost transparency in the matter:

	Disclosure of	Interest Statement
1.	Details of business activity of IndiaNivesh Securities Private Limited (INSPL)	INSPL is a Stock Broker registered with BSE, NSE and MCX - SX in all the major segments viz. Cash, F & O and CDS segments. INSPL is also a Depository Participant and registered with both Depository viz. CDSL and NSDL. Further, INSPL is a Registered Portfolio Manager and is registered with SEBI.
2.	Details of Disciplinary History of INSPL	No disciplinary action is / was running / initiated against INSPL
3.	Details of Associates of INSPL	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10-</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.
4.	Research analyst or INSPL or its relatives'/associates' financial interest in the subject company and nature of such financial interest	No (except to the extent of shares held by Research analyst or INSPL or its relatives'/associates')
5.	Research analyst or INSPL or its relatives'/associates' actual/beneficial ownership of 1% or more in securities of the subject company, at the end of the month immediately preceding the date of publication of the document.	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10-</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.
6.	Research analyst or INSPL or its relatives'/associates' any other material conflict of interest at the time of publication of the document	No
7.	Has research analyst or INSPL or its associates received any compensation from the subject company in the past 12 months	No
8.	Has research analyst or INSPL or its associates managed or co-managed public offering of securities for the subject company in the past 12 months	No
9.	Has research analyst or INSPL or its associates received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No
10.	Has research analyst or INSPL or its associates received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No
11.	Has research analyst or INSPL or its associates received any compensation or other benefits from the subject company or third party in connection with the document.	No
12.	Has research analyst served as an officer, director or employee of the subject company	No
13.	Has research analyst or INSPL engaged in market making activity for the subject company	No
14.	Other disclosures	No

INSPL, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. This information is subject to change, as per applicable law, without any prior notice. INSPL reserves the right to make modifications and alternations to this statement, as may be required, from time to time.

Definitions of ratings

BUY. We expect this stock to deliver more than 15% returns over the next 12 months.

HOLD. We expect this stock to deliver -15% to +15% returns over the next 12 months.

SELL. We expect this stock to deliver <-15% returns over the next 12 months.

Our target prices are on a 12-month horizon basis.

Other definitions

NR = Not Rated. The investment rating and target price, if any, have been arrived at due to certain circumstances not in control of INSPL

CS = Coverage Suspended. INSPL has suspended coverage of this company.

UR=Under Review. Such e invest review happens when any developments have already occurred or likely to occur in target company & INSPL analyst is waiting for some more information to draw conclusion on rating/target.

NA = Not Available or Not Applicable. The information is not available for display or is not applicable. NM = Not Meaningful. The information is not meaningful and is therefore excluded.

Research Analyst has not served as an officer, director or employee of Subject Company

One year Price history of the daily closing price of the securities covered in this note is available at <u>www.nseindia.com</u> and <u>www.economictimes.indiatimes.com/markets/stocks/stock-quotes</u>. (Choose name of company in the list browse companies and select 1 year in icon YTD in the price chart)



IndiaNivesh Securities Private Limited

601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007.

Tel: (022) 66188800 / Fax: (022) 66188899

e-mail: research@indianivesh.in | Website: www.indianivesh.in

Home



IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV.